How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/irritable-bowel-syndrome-characterized-by-constipation.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-11 · How we verify

Irritable bowel syndrome characterized by constipation — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Irritable bowel syndrome characterized by constipation (disease) competitive landscape: 4 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

4 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Irritable bowel syndrome characterized by constipation, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Ibsrela	AZD1722	Ardelyx Inc		Sodium/hydrogen exchanger 3	2019-01-01
Linzess	LINACLOTIDE	AbbVie	Guanylate Cyclase-C Agonist [EPC]	Heat-stable enterotoxin receptor	2012-01-01
Amitiza	LUBIPROSTONE	Sucampo Pharma Llc	Chloride Channel Activator [EPC]	Chloride channel protein 2	2006-01-01
Linzess	Linzess	TriHealth Inc.		Heat-stable enterotoxin receptor, Heat-stable enterotoxin receptor

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 1 drug in Irritable bowel syndrome characterized by constipation
AbbVie · 1 drug in Irritable bowel syndrome characterized by constipation
Ardelyx Inc · 1 drug in Irritable bowel syndrome characterized by constipation
Sucampo Pharma Llc · 1 drug in Irritable bowel syndrome characterized by constipation
TriHealth Inc. · 1 drug in Irritable bowel syndrome characterized by constipation

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Irritable bowel syndrome characterized by constipation:

Cite this brief

Drug Landscape (2026). Irritable bowel syndrome characterized by constipation — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/irritable-bowel-syndrome-characterized-by-constipation. Accessed 2026-06-11.

Irritable bowel syndrome characterized by constipation full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing